Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Epilim Chronosphere 250mg prolonged-release granules
Medicines register · Ireland

Epilim Chronosphere 250mg prolonged-release granules

Authorisation PA0540/150/006 · Sanofi-Aventis Ireland Limited T/A SANOFI

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 21 Nov 2026
Licence holder
Sanofi-Aventis Ireland Limited T/A SANOFI (all products →)
Active substances
Sodium valproate, Valproic acid
Clinical trials
3 clinical trials → 4 clinical trials →
Dosage form
Prolonged-release granules
Route of administration
Oral use
ATC codes
N03AG, N03AG01
First authorised
02/03/2007
Prescription status
Product subject to prescription which may be renewed (B)
Supply
Supply through pharmacies only
Legal basis
Full application (Article 8(3) of Directive No 2001/83/EC)

Sodium valproate: supply and approvals

13 authorised products on the HPRA list contain Sodium valproate. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 20 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 20 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 20 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

Valproic acid: supply and approvals

6 authorised products on the HPRA list contain Valproic acid. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 20 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 20 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 20 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 19 years (since 2 March 2007). The HPRA list marks it as marketed in Ireland.

Other medicines with Sodium valproate in Ireland

12 other products on the HPRA list contain Sodium valproate, from 2 licence holders; 12 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Epilim 100 mg Crushable TabletsSanofi-Aventis Ireland Limited T/A SANOFINational authorisation (PA)Marketed
Epilim Chrono 200mg Prolonged Release TabletsSanofi-Aventis Ireland Limited T/A SANOFINational authorisation (PA)Marketed
Epilim Chrono 300mg Prolonged Release TabletsSanofi-Aventis Ireland Limited T/A SANOFINational authorisation (PA)Marketed
Epilim Chrono 500mg Prolonged Release TabletsSanofi-Aventis Ireland Limited T/A SANOFINational authorisation (PA)Marketed
Epilim Chronosphere 100mg prolonged-release granulesSanofi-Aventis Ireland Limited T/A SANOFINational authorisation (PA)Marketed
Epilim Chronosphere 500mg prolonged-release granulesSanofi-Aventis Ireland Limited T/A SANOFINational authorisation (PA)Marketed
Epilim Enteric 200 mg gastro-resistant coated tabletsSanofi-Aventis Ireland Limited T/A SANOFINational authorisation (PA)Marketed
Epilim Enteric 500mg Gastro-resistant Coated TabletsSanofi-Aventis Ireland Limited T/A SANOFINational authorisation (PA)Marketed
Epilim Intravenous 400mg powder and solvent for solution for injection or infusionSanofi-Aventis Ireland Limited T/A SANOFINational authorisation (PA)Marketed
Epilim Liquid 200 mg/5ml Oral SolutionSanofi-Aventis Ireland Limited T/A SANOFINational authorisation (PA)Marketed
Epilim Syrup 200mg/5ml Oral SolutionSanofi-Aventis Ireland Limited T/A SANOFINational authorisation (PA)Marketed
Sodium Valproate Seacross 100 mg/ml solution for injection/infusionSeacross Pharma (Europe) LimitedNational authorisation (PA)Marketed

Other medicines with Valproic acid in Ireland

5 other products on the HPRA list contain Valproic acid, from 1 licence holder; 5 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Epilim Chrono 200mg Prolonged Release TabletsSanofi-Aventis Ireland Limited T/A SANOFINational authorisation (PA)Marketed
Epilim Chrono 300mg Prolonged Release TabletsSanofi-Aventis Ireland Limited T/A SANOFINational authorisation (PA)Marketed
Epilim Chrono 500mg Prolonged Release TabletsSanofi-Aventis Ireland Limited T/A SANOFINational authorisation (PA)Marketed
Epilim Chronosphere 100mg prolonged-release granulesSanofi-Aventis Ireland Limited T/A SANOFINational authorisation (PA)Marketed
Epilim Chronosphere 500mg prolonged-release granulesSanofi-Aventis Ireland Limited T/A SANOFINational authorisation (PA)Marketed

Other substances in ATC group N03AG

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 2 other active substances share the group N03AG with this product:

Tiagabine (3) · Vigabatrin (2)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Sanofi-Aventis Ireland Limited T/A SANOFI holds 54 products on the HPRA list, with 22 different active substances; 47 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.